306 related articles for article (PubMed ID: 17015894)
41. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
[TBL] [Abstract][Full Text] [Related]
42. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
[TBL] [Abstract][Full Text] [Related]
43. Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy.
Backhaus P; Huss S; Kösek V; Weckesser M; Rahbar K
Clin Nucl Med; 2018 Jun; 43(6):e184-e185. PubMed ID: 29688946
[TBL] [Abstract][Full Text] [Related]
44. [131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors.
Baulieu J; Resche I; Bardies M; Chauvet AF; Lecloirec J; Malhaire J; Thomas E; Faurous P; Sassolas G; Pourcelot L; Chatal J; Guilloteau D; Besnard JC
Nucl Med Biol; 2000 Nov; 27(8):809-813. PubMed ID: 11150715
[TBL] [Abstract][Full Text] [Related]
45. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
46. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.
Calais PJ; Turner JH
Ann Nucl Med; 2014 Jul; 28(6):531-9. PubMed ID: 24687907
[TBL] [Abstract][Full Text] [Related]
47. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
van Essen M; Krenning EP; Bakker WH; de Herder WW; van Aken MO; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1219-27. PubMed ID: 17260141
[TBL] [Abstract][Full Text] [Related]
48. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
Breeman WA; Mearadji A; Capello A; Bernard BF; van Eijck CH; Krenning EP; de Jong M
Int J Cancer; 2003 Apr; 104(3):376-9. PubMed ID: 12569562
[TBL] [Abstract][Full Text] [Related]
49. Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature.
Minutoli F; Amato E; Sindoni A; Cardile D; Conti A; Herberg A; Baldari S
Cancer Biother Radiopharm; 2014 Jun; 29(5):193-9. PubMed ID: 24811687
[TBL] [Abstract][Full Text] [Related]
50. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
51. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
Bartolomei M; Bodei L; De Cicco C; Grana CM; Cremonesi M; Botteri E; Baio SM; Aricò D; Sansovini M; Paganelli G
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1407-16. PubMed ID: 19319527
[TBL] [Abstract][Full Text] [Related]
52. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Mar; 40(3):237-40. PubMed ID: 25608146
[TBL] [Abstract][Full Text] [Related]
53. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
[TBL] [Abstract][Full Text] [Related]
54. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
55. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.
Alexandru D; Glantz MJ; Kim L; Chamberlain MC; Bota DA
Cancer; 2011 Oct; 117(19):4506-11. PubMed ID: 21446045
[TBL] [Abstract][Full Text] [Related]
56. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
Hata M; Tokuuye K; Kagei K; Sugahara S; Nakayama H; Fukumitsu N; Hashimoto T; Mizumoto M; Ohara K; Akine Y
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):786-93. PubMed ID: 17379439
[TBL] [Abstract][Full Text] [Related]
57. The Use of 68Ga-DOTA-(Tyr3)-Octreotate PET/CT for Improved Target Definition in Radiotherapy Treatment Planning of Meningiomas - A Case Report.
Grzbiela H; Tarnawski R; D'Amico A; Stąpór-Fudzińska M
Curr Radiopharm; 2015; 8(1):45-8. PubMed ID: 25808961
[TBL] [Abstract][Full Text] [Related]
58. Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.
Schneider JR; Shatzkes DR; Scharf SC; Tham TM; Kulason KO; Buteau FA; Del Prete M; Chakraborty S; Anderson TA; Asiry S; Beauregard JM; Langer DJ; Costantino PD; Boockvar JA
Oper Neurosurg (Hagerstown); 2018 Dec; 15(6):100-109. PubMed ID: 29554305
[TBL] [Abstract][Full Text] [Related]
59. Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma.
Arvold ND; Lessell S; Bussiere M; Beaudette K; Rizzo JF; Loeffler JS; Shih HA
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1166-72. PubMed ID: 19406585
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]